<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272387</url>
  </required_header>
  <id_info>
    <org_study_id>13-0223</org_study_id>
    <nct_id>NCT02272387</nct_id>
  </id_info>
  <brief_title>Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?</brief_title>
  <official_title>Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary aim is to evaluate whether Vitamin D deficiency causes depressive symptoms in&#xD;
      antepartum and postpartum depression and whether early correction of Vitamin D deficiency&#xD;
      improves these symptoms.&#xD;
&#xD;
      Our secondary aims evaluate maternal and fetal outcomes including antepartum, intrapartum,&#xD;
      and immediate postpartum complications. We are also evaluating the effectiveness of a common&#xD;
      vitamin D treatment regimen used outside of pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study recruitment will be at a single center in our pregnant private and clinic&#xD;
      population. We will recruit eligible pregnant women 20 weeks 0 days or less. On study entry,&#xD;
      patients will complete a demographic survey, vitamin D exposure survey, and an Edinburgh&#xD;
      Postnatal Depression Score (EPDS) questionnaire. Baseline vitamin D levels will be obtained&#xD;
      using a 25 OH D (vitamin D) assay.&#xD;
&#xD;
      Women found to be vitamin D deficient/insufficient will be approached for randomization to&#xD;
      vitamin D3 (Cholecalciferol) 50,000 IU/week x 8 weeks + prenatal vitamin versus placebo +&#xD;
      prenatal vitamin. A repeat 25 OH D sample plus a vitamin D exposure and EPDS questionnaires&#xD;
      will be obtained between 24-28 weeks gestation upon completing treatment. All patients will&#xD;
      then be kept on maintenance vitamin D until delivery (total vitamin D 800IU/day which&#xD;
      includes prenatal vitamin). Delivery 25 OH D samples will be collected on all women. At&#xD;
      delivery, these women will also complete vitamin D exposure and EPDS questionnaires. Maternal&#xD;
      and fetal outcome data will be collected on all patients.&#xD;
&#xD;
      As for vitamin D sufficient patients, they will be followed with vitamin D exposure and EPDS&#xD;
      questionnaires at 24-28 weeks and delivery. A 25 OH D sample will be obtained at delivery for&#xD;
      these women. Maternal and fetal outcome data will be obtained.&#xD;
&#xD;
      For vitamin D deficient women declining randomization, they will be given vitamin D repletion&#xD;
      based on their preference after counseling. We will continue to follow their questionnaires&#xD;
      and outcomes similarly to the vitamin D sufficient group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment and limited research staffing&#xD;
  </why_stopped>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">April 14, 2016</completion_date>
  <primary_completion_date type="Actual">April 14, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antepartum and Postpartum Depressive symptoms</measure>
    <time_frame>9 months</time_frame>
    <description>We will be using an Edinburgh Postnatal Depression Scale (EPDS) questionnaire to monitor depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidities</measure>
    <time_frame>Antepartum and Delivery</time_frame>
    <description>Composite maternal complications: preeclampsia, GDM, delivery complications, chorioamnionitis, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal morbidities</measure>
    <time_frame>Antepartum and delivery</time_frame>
    <description>Composite outcomes: SGA, IUGR, low apgars, low cord gases, hydramnios, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Depression</condition>
  <condition>Postpartum Depression</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (Cholecalciferol)</intervention_name>
    <arm_group_label>Vitamin D3 (cholecalciferol) treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vitamin D placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evaluation at Roosevelt Hospital (Receiving prenatal care with St Luke's Roosevelt&#xD;
             Hospital center private physicians and clinic) by 20w0d gestation.&#xD;
&#xD;
          -  Planned delivery at Roosevelt Hospital Labor &amp; Delivery&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-english or non-spanish speaking&#xD;
&#xD;
          -  Currently on anti-depressants/mood stabilizing medications&#xD;
&#xD;
          -  Medical comorbidities affecting vitamin D absorption or metabolism:Bone disease&#xD;
             (osteoporosis, osteomalacia); Malabsorption disorders (cystic fibrosis, inflammatory&#xD;
             bowel disease, roux-en-y bariatric surgery); Chronic kidney disease; Severe liver&#xD;
             disease; Granuloma forming disorders (active tuberculosis, sarcoidosis);Parathyroid&#xD;
             disease; Lymphoma; HIV on HAART medication; anti-seizure medications.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Sinai Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

